Profusa, Inc. (NASDAQ:PFSA) Sees Large Decline in Short Interest

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 123,461 shares, a decrease of 57.2% from the May 31st total of 288,318 shares. Based on an average daily trading volume, of 412,104 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.7% of the shares of the stock are sold short.

Profusa Price Performance

NASDAQ PFSA traded up $0.01 during trading on Wednesday, reaching $0.13. The company’s stock had a trading volume of 3,026,111 shares, compared to its average volume of 3,849,541. The firm has a fifty day moving average of $0.36 and a 200 day moving average of $2.72. Profusa has a one year low of $0.10 and a one year high of $180.00. The stock has a market capitalization of $587,160.00, a PE ratio of -0.00 and a beta of 0.35.

Profusa (NASDAQ:PFSA) last issued its quarterly earnings data on Friday, May 15th. The company reported ($2.05) EPS for the quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PFSA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen upgraded shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Profusa currently has a consensus rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.